The significance of subclinical rejection

Clinical Transplantation

Volumn 23, Issue 2, 2009, Pages 150-156

  El Amm, Jose Marie ^a   Gruber, Scott A ^b  

^a INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Protocol biopsy; Renal transplantation; Subclinical

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MIZORIBINE; MOLECULAR MARKER; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; BIOPSY; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FIBROSIS; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; LONG TERM CARE; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SUBCLINICAL GRAFT REJECTION;

ACUTE DISEASE; GLOMERULAR FILTRATION RATE; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; PULSE THERAPY, DRUG; RISK FACTORS;

EID: 64349093997     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00888.x     Document Type: Review

References (56)

1. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
2. Nankivell BJ, Borrows RJ, Fung CL et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004: 78: 242.
3. Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998: 9: 2129.
4. Veronese FV, Manfro RC, Roman FR et al. Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 2005: 19: 518.
5. Furness PN, Taub N. International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP project. Kidney Int 2001: 60: 1998.
6. Mengel M, Gwinner W, Schwarz A et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007: 7: 356.
7. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006: 6: 2006.
8. Thaunat O, Legendre C, Morelon E, Kreis H, Mamzer-Bruneel MF. To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation 2007: 84: 671.
9. Curtis JJ. Protocol biopsy: Today's fine-needle aspiration biopsy? Transplantation 2007: 84: 677.
10. Rush D, Arlen D, Boucher A et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007: 7: 2538.
11. Meier-Kriesche HU, Schold JD, Srinivas TR et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
12. Wilczek HE. Percutaneous needle biopsy of the renal allograft. A clinical safety evaluation of 1129 biopsies. Transplantation 1990: 50: 790.
13. Furness PN, Philpott CM, Chorbadjian MT et al. Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplantation 2003: 76: 969.
14. Schwarz A, Gwinner W, Hiss M et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005: 5: 1992.
15. El-Amm JM, Sethi A, Doshi M et al. Utility and safety of surveillance biopsy in a predominantly African American kidney transplant population on a steroid avoidance protocol. J Am Soc Nephrol 2007: 18: 447A.
16. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326.
17. Vidhun J, Masciandro J, Varich L et al. Safety and risk stratification of percutaneous biopsies of adult sized renal allografts in infant and older pediatric recipients. Transplantation 2003: 76: 552.
18. Shapiro R, Randhawa P, Jordan ML et al. An analysis of early renal transplant protocol biopsies - the high incidence of subclinical tubulitis. Am J Transplant 2001: 1: 47.
19. Gloor JM, Cohen AJ, Lager DJ et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002: 73: 1965.
20. Colvin RB. Eye of the needle. Am J Transplant 2007: 7: 267.
21. Nankivell BJ, Fenton-Lee CA,Kuypers DR et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001: 71: 515.
22. Choi BS, Shin MJ, Shin SJ et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year experience at a single center. Am J Transplant 2005: 5: 1354.
23. Rush DN, Karpinski ME, Nickerson P et al. Does subclinical rejection contribute to chronic rejection in renal transplant patients? Clin Transplant 1999: 13: 441.
24. Roberts IS, Reddy S, Russell C et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 2004: 77: 1194.
25. Birk PE, Stannard KM, Konrad HB et al. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. Pediatr Transplant 2004: 8: 29.
26. Anil Kumar MS, Moritz MJ, Saaed MI et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005: 5: 1976.
27. Haririan A, Sillix DH, Morawski K et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant 2006: 6: 2396.
28. Heilman RL, Reddy KS, Mazur MJ et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc 2006: 38: 1307.
29. Kee TY-S, Chapman JR, O'Connell PJ et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation 2006: 82: 36.
30. Rowshani AT, Scholten EM, Bemelman F et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006: 17: 305.
31. Seron D, Moreso F, Bover J et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997: 51: 310.
32. Scholten EM, Rowshani AT, Cremers S et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006: 17: 2622.
33. Schweitzer EJ, Drachenberg CB, Anderson L et al. Significance of the Banff borderline biopsy. Am J Kidney Dis 1996: 28: 585.
34. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001: 344: 947.
35. Kummer JA, Wever PC, Kamp AM et al. Expression of granzyme A and B proteins by cytotoxic lymphocytes involved in acute renal allograft rejection. Kidney Int 1995: 47: 70.
36. Rowshani AT, Florquin S, Bemelman F et al. Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: A potential mechanism for stable renal function in patients with subclinical rejection. Kidney Int 2004: 66: 1417.
37. Grimm PC, Mc Kenna R, Nickerson P et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999: 10: 1582.
38. Seron D, Diaz-Gallo C, Grino JM et al. Characterization of interstitial infiltrate in early renal allograft biopsies in patients with stable renal function. Transplant Proc 1991: 23: 1267.
39. Ibernon M, Goma M, Moreso F et al. Subclinical rejection impairs glomerular adaptation after renal transplantation. Kidney Int 2006: 70: 557.
40. Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003: 14: 1046.
41. Moreso F, Ibernon M, Goma M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006: 6: 747.
42. Cosio FG, Grande JP, Wadei H et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005: 5: 2464.
43. Smith RN, Kawai T, Boskovic S et al. Chronic antibody mediated rejection of renal allografts: Pathological, serological and immunologic features in nonhuman primates. Am J Transplant 2006: 6: 1790.
44. Haas M, Montgomery RA, Segev DL et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007: 7: 576.
45. Halloran PF. Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2002: 2: 195.
46. Einecke G, Fairhead T, Hidalgo LG et.al. Tubulitis and epithelial cell alterations in mouse kidney transplant rejection are independent of CD103, perforin or granzymes A/B. Am J Transplant 2006: 6: 2109.
47. Halloran PF, Einecke G. Microarrays and transcriptome analysis in renal transplantation. Nat Clin Pract Nephrol 2006: 2: 2.
48. Akalin E, Hendrix RC, Polavarapu RG et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 2001: 72: 948.
49. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003: 349: 125.
50. Mansfield ES, Sarwal MM. Arraying the orchestration of allograft pathology. Am J Transplant 2004: 4: 853.
51. Hoffmann SC, Kampen RL, Amur S et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplant 2002: 74: 916.
52. Veronese FV, Noronha IL, Manfro RC et al. Prevalence and immunohistochemical findings of subclinical kidney allograft rejection and its association with graft outcome. Clin Transplant 2004: 18: 357.
53. Gough J, Rush D, Jeffery J et al. Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. Nephrol Dial Transplant 2002: 17: 1081.
54. Rush D. Protocol biopsies should be part of the routine management of kidney transplant recipients. Pro Am J Kidney Dis 2002: 40: 671.
55. Nickerson P, Jeffery J, Gough J et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study. J Am Soc Nephrol 1999: 10: 1801.
56. Gruber SA. Subclinical acute rejection treated as clinical acute rejection: Same intervention, same morbidity, masked endpoint, equal reporting. Transplantation 2006: 82: 1550.